Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1
- Data published in official journal of Molecular Genetics and Metabolism Reports: Evidence of a change in cholesterol homeostasis in peripheral organs and the brain after the initial infusion Trappsol® Cyclo™ was detected in the CSF Completers had an 88.9%...
Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol® Cyclo™ for Alzheimer’s Disease
GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases,...
Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement
GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases,...
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
Company on track to complete enrollment in ongoing pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) by year end 2023 GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo...
Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)
GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases,...
Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules
GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases,...
Cyclo Therapeutics Provides Business Update and Reports Full Year 2022 Financial Results
Pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) projected 40% enrolled by the end of March; Company on track to complete enrollment by year end 2023 Phase 2b study of Trappsol®...
Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements
Continued progress in ongoing pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) with 35% of expected enrollment completed, on track to complete enrollment by year end 2023 Patient...
Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Thursday, January 19th at 11:00 AM ET GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and...
Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease
- Biologic similarities demonstrated between Niemann-Pick Disease Type C and Alzheimer's disease, including cholesterol accumulation in regions of the brain, elevated levels of Tau in CSF, and amyloid plaques in the brain, bolsters rationale for studying...